title: [Drug promiscuity].
abstract: It is essential for a successful drug to possess two basic characteristics: satisfactory pharmacological action with sufficient potency and selectivity; good druggability with eligible physicochemical, pharmacokinetic and safety profiles, as well as structural novelty. Promiscuity is defined as the property of a drug to act with multiple molecular targets and exhibit distinct pharmacological effects. Promiscuous drugs are the basis of polypharmacology and the causes for side effects and unsuitable DMPK. Drug promiscuity originates from protein promiscuity. In order to accommodate, metabolize and excrete various endo- and exogenous substances, protein acquired the capability during evolution to adapt a wide range of structural diversity, and it is unnecessary to reserve a specific protein for every single ligand. The structures of target proteins are integration of conservativity and diversity. The former is represented by the relatively conservative domains for secondary structures folding, which leads to overlapping in ligand-binding and consequent cross-reactivity of ligands. Diversity, however, embodies the subtle difference in structures. Similar structural domain may demonstrate different functions due to alteration of amino acid sequences. The phenomenon of promiscuity may facilitate the "design in" of multi-target ligands for the treatment of complicated diseases, whereas it should be appropriately handled to improve druggability. Therefore, one of the primary goals in drug design is to scrutinize and manipulate the "merits and faults" of promiscuity. This review discusses the application of promiscuity in drug design for receptors, enzymes, ion channels and cytochrome P450. It also briefly describes the methods to predict ligand promiscuity based on either target or ligand structures.
authors.affiliation: Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China. zrguo@imm.ac.cn
authors.forename: Zong-ru
authors.initials: ZR
authors.lastname: Guo
mesh_terms: D003577:Cytochrome P-450 Enzyme System / Q000737:chemistry*; D015195:Drug Design; D055808:Drug Discovery; D018432:Drug Resistance, Multiple; D064420:Drug-Related Side Effects and Adverse Reactions; D004791:Enzyme Inhibitors / Q000737:chemistry; D007473:Ion Channels / Q000737:chemistry; D008024:Ligands; D004364:Pharmaceutical Preparations / Q000737:chemistry* / Q000378:metabolism; D010599:Pharmacokinetics; D010600:Pharmacology; D000077297:Pregnane X Receptor; D011485:Protein Binding; D011487:Protein Conformation; D043562:Receptors, G-Protein-Coupled / Q000737:chemistry; D011987:Receptors, Steroid / Q000819:agonists / Q000037:antagonists & inhibitors
chemical_list: D004791:Enzyme Inhibitors; D007473:Ion Channels; D008024:Ligands; D004364:Pharmaceutical Preparations; D000077297:Pregnane X Receptor; D043562:Receptors, G-Protein-Coupled; D011987:Receptors, Steroid; D003577:Cytochrome P-450 Enzyme System